MarketCap
Facebook
X
TelegramAnnual report 2020
added 12-16-2023
Burford Capital Limited Total Shareholders Equity 2011-2026 | BUR
Annual Total Shareholders Equity Burford Capital Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.7 B | 1.53 B | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.7 B | 1.53 B | 1.62 B |
Quarterly Total Shareholders Equity Burford Capital Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 1.66 B | - | - | - | 1.5 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.66 B | 1.5 B | 1.58 B |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M |  USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 220.53 | 2.32 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.63 | 2.05 % | $ 918 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
CytomX Therapeutics
CTMX
|
99 M | $ 4.18 | -1.42 % | $ 577 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M |  Canada |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | USA |
 |
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.34 | 1.14 % | $ 342 M | Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
148 M | $ 8.33 | 1.83 % | $ 111 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 47.37 | 2.02 % | $ 4.26 B |  Schweiz |
 |
Cyclacel Pharmaceuticals
CYCC
|
-2.17 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Eton Pharmaceuticals
ETON
|
26.2 M | $ 24.01 | 4.53 % | $ 646 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
-21.3 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
76.6 M | $ 4.46 | 3.36 % | $ 855 M | Canada |
 |
Homology Medicines
FIXX
|
42 M | - | 0.77 % | $ 53.4 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
GT Biopharma
GTBP
|
5.79 M | $ 0.46 | -3.14 % | $ 2.54 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Halozyme Therapeutics
HALO
|
48.8 M | $ 63.2 | 1.87 % | $ 7.57 B | USA |